Pre-incision Versus Post-incision Local Anesthetic During Robotic Sacrocolpopexy

NCT ID: NCT04996251

Last Updated: 2024-12-10

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 129 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-07-30
• Study Completion Date: 2023-06-30

Brief Summary

Obtaining Likest-pain scale score on postoperative day one after injection of local anesthetic into incision sites of a laparoscopic/robotic-assisted sacrocolpopexy

Detailed Description

Pelvic organ prolapse is becoming more common as women's life expectancy is increasing and the prevalence of obesity is rising. Many women undergo pelvic reconstructive surgery to treat their prolapse and improve their quality of life. The incidence of pelvic organ prolapse is 1.5-1.8 surgeries per 1,000 women years. Approximately 300,000 pelvic reconstructive surgeries are performed each year in the United States. There is a wide variety in surgical approaches and procedures for prolapse. One such procedure is a sacrocolpopexy in which the cervix or vaginal cuff is lifted to the anterior longitudinal ligament overlying the sacrum via a mesh graft. This can be done in a minimally invasive fashion with a laparoscopic or robotic approach or in an open abdominal approach. Numerous studies have shown this procedure to have a high success rate and long-term durability. As robotic/laparoscopic approach to surgery has shown shorter hospital-stays and improved patient outcomes, the robotic-assisted sacrocolpopexy has been rapidly incorporated into clinical practice.

In general, surgery causes a release of painful chemical mediators which has led to increased narcotic use, increased narcotic addiction, and number of pills prescribed. Most individuals who undergo surgery will require narcotics postoperatively to control their pain and some individuals have to extend their hospital stay until adequate pain control is achieved. Our study is aimed to reduce narcotic use, decrease hospital stay due to pain issues and determine if timing of adjunct pain medication improves pain scales for patients.

As postoperative pain after minimally invasive surgery is complex, specialists suggest that the effective analgesic treatment should be a multimodal approach. Use of local anesthetic with bupivacaine at robotic/laparoscopic trocar sites is the standard of care, however, there is no standard as to optimal timing that is most beneficial for patients to decrease pain. Currently, bupivacaine is used by providers at the trocar sites at either the beginning of the case or at the end of the case. From clinical observation, it appears that postoperative pain levels reported from patients receiving either at the beginning of surgery (pre-) or end (post-incision) of the surgery are similar. This study aims to examine the difference in postoperative day one pain levels reported by patients between the two infiltration methods

Conditions

Pain, Postoperative

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: SINGLE

Study Groups

subcutaneous infiltration pre-incision

Marcaine (bupivacaine) injected in the umbilical port site subcutaneously, while in the other 4 sites injection under direct visualization

Group Type: EXPERIMENTAL

Bupivacaine Injection

Intervention Type: DRUG

0.25% Bupivacaine being used as local anesthetic to inject into incision sites of tracer sites during a laparoscopic/robotic-assisted sacrocolpopexy

subcutaneous infiltration post-incision

local anesthetic infiltrated subcutaneously at the end of the procedure after trocar removal and after skin closure with suture

Group Type: EXPERIMENTAL

Bupivacaine Injection

Intervention Type: DRUG

0.25% Bupivacaine being used as local anesthetic to inject into incision sites of tracer sites during a laparoscopic/robotic-assisted sacrocolpopexy

Interventions

Bupivacaine Injection

0.25% Bupivacaine being used as local anesthetic to inject into incision sites of tracer sites during a laparoscopic/robotic-assisted sacrocolpopexy

Intervention Type: DRUG

Other Intervention Names

Marcaine

Eligibility Criteria

Inclusion Criteria

• Females 18+ years old who are undergoing robotic/laparoscopic assisted sacrocolpopexy

• With/without hysterectomy
• With/without unilateral/bilateral salpingectomy
• With/without unilateral/bilateral oophorectomy
• With/without mid-urethral sling
• With/without anterior/posterior vaginal repair

• English or Spanish speaking
• Weight ≥ 120 lb

Exclusion Criteria

• Females < 18 years old

• Chronic pelvic pain/chronic pain syndromes
• Fibromyalgia
• Pregnant or breastfeeding patients
• Concomitant procedure for hernia repair or rectal prolapse repair
• Undergoing primary vaginal prolapse surgery
• Contraindications to taking the following medications: Bupivacaine
• Patients who weight is < 120lb
• Hypersensitivity to bupivacaine hydrochloride, amide-type local anesthetics, or any component of the formulation
• Pudendal or spinal nerve block given during surgery

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Northwell Health

OTHER

Sponsor Role: lead

Responsible Party

Harvey Winkler, MD

System Chief of Urogynecology Division; Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

North Shore University Hospital

Manhasset, New York, United States

Countries

United States

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Document Type: Informed Consent Form

View Document

Other Identifiers

21-0422

Identifier Type: -

Identifier Source: org_study_id